Epicrispr Biotechnologies reported raising $177 Million in an initial SEC Form D filing, from an offering of $213 Million
Amount Raised
$177 Million
Round Type
Series C
South San FranciscoBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
Epicrispr Biotechnologies has secured a $90 million Series C financing round, oversubscribed and supported by a notable array of investors including Fidelity and Sanofi Ventures. This funding will focus on advancing EPI-321, its lead candidate for treating facioscapulohumeral muscular dystrophy, through pivotal clinical development. The company aims to demonstrate that gene silencing can become a viable therapeutic option without altering DNA. This significant investment reflects growing confidence in epigenetics as a therapeutic modality.
Quick answer
Epicrispr Biotechnologies raised $177 Million in a Series C round, dated August 10, 2026. Investors: Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, Readout Capital, Angelini Ventures, Abrdn Inc. and Janus Henderson Investors. Epicrispr Biotechnologies is based in South San Francisco, California, United States.
- How much did Epicrispr Biotechnologies raise?
- Epicrispr Biotechnologies raised $177 Million in a Series C round on August 10, 2026.
- Who invested in Epicrispr Biotechnologies?
- Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, Readout Capital, Angelini Ventures, Abrdn Inc. and Janus Henderson Investors are named as investors in this round.
- What does Epicrispr Biotechnologies do?
- Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases.
- Where is Epicrispr Biotechnologies based and how big is it?
- Epicrispr Biotechnologies is based in South San Francisco, California, United States. Fundz records about 38 employees.
- Who are the decision-makers at Epicrispr Biotechnologies?
- Fundz holds 4 contacts at Epicrispr Biotechnologies, including the Head of Technology Development. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Epicrispr Biotechnologies that raised within 45 days of this round, from Fundz verified event records.
- Typewriter Therapeutics raised $56M (Series A) on September 2, 2026.
- Rejuvenation Technologies raised an undisclosed amount on September 24, 2026.
- Kasvu Therapeutics raised $34M (Series A) on September 24, 2026.
- ViferaXS raised $14M (Series A) on September 23, 2026.
- Kinoxis Therapeutics raised $5M (Seed) on September 23, 2026.
- Aqua Medical raised an undisclosed amount (Series B) on September 23, 2026.
Who to call at Epicrispr Biotechnologies, and when
A new round usually means Epicrispr Biotechnologies is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Epicrispr Biotechnologies raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Epicrispr Biotechnologies, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Epicrispr Biotechnologies. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Epicrispr Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Epicrispr Biotechnologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.